...
首页> 外文期刊>Journal of Translational Medicine >Huh-7 cell line as an alternative cultural model for the production of human like erythropoietin (EPO)
【24h】

Huh-7 cell line as an alternative cultural model for the production of human like erythropoietin (EPO)

机译:Huh-7细胞系可作为人类产生的促红细胞生成素(EPO)的替代培养模型

获取原文
           

摘要

Background and Aims Erythropoietin (EPO) is a glycoprotein hormone which is required to regulate the production of red blood cells. Deficiency of EPO is known to cause anemia in chronically infected renal patients and they require regular blood transfusion. Availability of recombinant EPO has eliminated the need for blood transfusion and now it is extensively used for the treatment of anemia. Glycosylation of erythropoietin is essential for its secretion, stability, protein conformation and biological activity. However, maintenance of human like glycosylation pattern during manufacturing of EPO is a major challenge in biotechnology. Currently, Chinese hamster ovary (CHO) cell line is used for the commercial production of erythropoietin but this cell line does not maintain glycosylation resembling human system. With the trend to eliminate non-human constituent from biopharmaceutical products, as a preliminary approach, we have investigated the potential of human hepatoma cell line (Huh-7) to produce recombinant EPO. Materials and methods Initially, the secretory signal and Kozak sequences was added before the EPO mature protein sequence using overlap extension PCR technique. PCR-amplified cDNA fragments of EPO was inserted into mammalian expression vector under the control of the cytomegalovirus (CMV) promoter and transiently expressed in CHO and Huh-7 cell lines. After RT-PCR analysis, ELISA and Western blotting was performed to verify the immunochemical properties of secreted EPO. Results Addition of secretory signal and Kozak sequence facilitated the extra-cellular secretion and enhanced the expression of EPO protein. Significant expression (P Conclusion Huh-7 cell line has a great potential to produce glycosylated EPO, suggesting the use of this cell line to produce glycoproteins of the therapeutic importance resembling to the natural human system.
机译:背景与目的促红细胞生成素(EPO)是一种糖蛋白激素,是调节红细胞产生所必需的。已知EPO缺乏会在慢性感染的肾病患者中引起贫血,需要定期输血。重组EPO的可用性消除了输血的需要,现在已广泛用于治疗贫血。促红细胞生成素的糖基化对其分泌,稳定性,蛋白质构象和生物活性至关重要。然而,在EPO的制造过程中维持像人一样的糖基化模式是生物技术中的主要挑战。当前,中国仓鼠卵巢(CHO)细胞系用于促红细胞生成素的商业生产,但是该细胞系不能维持类似于人系统的糖基化。作为一种从生物药品中消除非人类成分的趋势,作为一种初步方法,我们研究了人类肝癌细胞系(Huh-7)产生重组EPO的潜力。材料和方法首先,使用重叠延伸PCR技术在EPO成熟蛋白序列之前添加分泌信号和Kozak序列。 EPO的PCR扩增cDNA片段在巨细胞病毒(CMV)启动子的控制下插入哺乳动物表达载体,并在CHO和Huh-7细胞系中瞬时表达。在RT-PCR分析之后,进行ELISA和Western印迹以验证分泌的EPO的免疫化学特性。结果增加分泌信号和Kozak序列促进细胞外分泌,增强EPO蛋白的表达。显着表达(P结论Huh-7细胞系具有产生糖基化EPO的巨大潜力,这表明该细胞系可用于产生与天然人系统相似的具有治疗重要性的糖蛋白。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号